Literature DB >> 29434334

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

Sattva S Neelapu1, Sudhakar Tummala2, Partow Kebriaei3, William Wierda4, Frederick L Locke5, Yi Lin6, Nitin Jain4, Naval Daver4, Alison M Gulbis7, Sherry Adkins1, Katayoun Rezvani3, Patrick Hwu8, Elizabeth J Shpall3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29434334      PMCID： PMC6716606          DOI： 10.1038/nrclinonc.2018.20

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  11 in total

1.  Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  Julie C Fitzgerald; Scott L Weiss; Shannon L Maude; David M Barrett; Simon F Lacey; J Joseph Melenhorst; Pamela Shaw; Robert A Berg; Carl H June; David L Porter; Noelle V Frey; Stephan A Grupp; David T Teachey
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

2.  Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

Authors:  Partow Kebriaei; Harjeet Singh; M Helen Huls; Matthew J Figliola; Roland Bassett; Simon Olivares; Bipulendu Jena; Margaret J Dawson; Pappanaicken R Kumaresan; Shihuang Su; Sourindra Maiti; Jianliang Dai; Branden Moriarity; Marie-Andrée Forget; Vladimir Senyukov; Aaron Orozco; Tingting Liu; Jessica McCarty; Rineka N Jackson; Judy S Moyes; Gabriela Rondon; Muzaffar Qazilbash; Stefan Ciurea; Amin Alousi; Yago Nieto; Katy Rezvani; David Marin; Uday Popat; Chitra Hosing; Elizabeth J Shpall; Hagop Kantarjian; Michael Keating; William Wierda; Kim Anh Do; David A Largaespada; Dean A Lee; Perry B Hackett; Richard E Champlin; Laurence J N Cooper
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

Review 3.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

4.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

5.  Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Authors:  Stephen J Schuster; Jakub Svoboda; Elise A Chong; Sunita D Nasta; Anthony R Mato; Özlem Anak; Jennifer L Brogdon; Iulian Pruteanu-Malinici; Vijay Bhoj; Daniel Landsburg; Mariusz Wasik; Bruce L Levine; Simon F Lacey; Jan J Melenhorst; David L Porter; Carl H June
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

6.  Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

Authors:  David T Teachey; Michael R Bishop; David G Maloney; Stephan A Grupp
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

Review 7.  Adult haemophagocytic syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Armando López-Guillermo; Munther A Khamashta; Xavier Bosch
Journal:  Lancet       Date:  2013-11-27       Impact factor: 79.321

8.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Authors:  David L Porter; Wei-Ting Hwang; Noelle V Frey; Simon F Lacey; Pamela A Shaw; Alison W Loren; Adam Bagg; Katherine T Marcucci; Angela Shen; Vanessa Gonzalez; David Ambrose; Stephan A Grupp; Anne Chew; Zhaohui Zheng; Michael C Milone; Bruce L Levine; Jan J Melenhorst; Carl H June
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

9.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

Review 10.  How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?

Authors:  AnnaCarin Horne; Ronny Wickström; Michael B Jordan; E Ann Yeh; Ahmed Naqvi; Jan-Inge Henter; Gritta Janka
Journal:  Curr Treat Options Neurol       Date:  2017-01       Impact factor: 3.598
View more
  26 in total

1.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

Authors:  Enli Liu; David Marin; Pinaki Banerjee; Homer A Macapinlac; Philip Thompson; Rafet Basar; Lucila Nassif Kerbauy; Bethany Overman; Peter Thall; Mecit Kaplan; Vandana Nandivada; Indresh Kaur; Ana Nunez Cortes; Kai Cao; May Daher; Chitra Hosing; Evan N Cohen; Partow Kebriaei; Rohtesh Mehta; Sattva Neelapu; Yago Nieto; Michael Wang; William Wierda; Michael Keating; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  N Engl J Med       Date:  2020-02-06       Impact factor: 91.245

Review 2.  Advanced Therapy Medicinal Products and the Changing Role of Academia.

Authors:  Christoph Priesner; Martin Hildebrandt
Journal:  Transfus Med Hemother       Date:  2022-05-16       Impact factor: 4.040

Review 3.  Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review).

Authors:  Xiaobo Peng; Ling Chen; Longpei Chen; Bin Wang; Yiran Wang; Xianbao Zhan
Journal:  Exp Ther Med       Date:  2021-02-10       Impact factor: 2.447

Review 4.  Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.

Authors:  Allison Barz Leahy; Caitlin W Elgarten; Stephan A Grupp; Shannon L Maude; David T Teachey
Journal:  Expert Rev Anticancer Ther       Date:  2018-10       Impact factor: 3.627

Review 5.  Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.

Authors:  Dristhi Ragoonanan; Sajad J Khazal; Hisham Abdel-Azim; David McCall; Branko Cuglievan; Francesco Paolo Tambaro; Ali Haider Ahmad; Courtney M Rowan; Cristina Gutierrez; Keri Schadler; Shulin Li; Matteo Di Nardo; Linda Chi; Alison M Gulbis; Basirat Shoberu; Maria E Mireles; Jennifer McArthur; Neena Kapoor; Jeffrey Miller; Julie C Fitzgerald; Priti Tewari; Demetrios Petropoulos; Jonathan B Gill; Christine N Duncan; Leslie E Lehmann; Sangeeta Hingorani; Joseph R Angelo; Rita D Swinford; Marie E Steiner; Fiorela N Hernandez Tejada; Paul L Martin; Jeffery Auletta; Sung Won Choi; Rajinder Bajwa; Natalie Dailey Garnes; Partow Kebriaei; Katayoun Rezvani; William G Wierda; Sattva S Neelapu; Elizabeth J Shpall; Selim Corbacioglu; Kris M Mahadeo
Journal:  Nat Rev Clin Oncol       Date:  2021-02-19       Impact factor: 65.011

Review 6.  Strategies for Manipulating T Cells in Cancer Immunotherapy.

Authors:  Hyang-Mi Lee
Journal:  Biomol Ther (Seoul)       Date:  2022-03-10       Impact factor: 4.231

7.  Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.

Authors:  Melissa R Hines; Camille Keenan; Gabriela Maron Alfaro; Cheng Cheng; Yinmei Zhou; Akshay Sharma; Caitlin Hurley; Kim E Nichols; Stephen Gottschalk; Brandon M Triplett; Aimee C Talleur
Journal:  Br J Haematol       Date:  2021-07-15       Impact factor: 6.998

Review 8.  Pediatric cancer research: Surviving COVID-19.

Authors:  Jeffery J Auletta; Peter C Adamson; Jonathan E Agin; Pamela Kearns; Scott Kennedy; Mark W Kieran; Donna M Ludwinski; Leona J Knox; Kristi McKay; Pia Rhiner; Carol J Thiele; Timothy P Cripe
Journal:  Pediatr Blood Cancer       Date:  2020-06-18       Impact factor: 3.838

9.  The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.

Authors:  Bianca Simon; Manuel Wiesinger; Johannes März; Kilian Wistuba-Hamprecht; Benjamin Weide; Beatrice Schuler-Thurner; Gerold Schuler; Jan Dörrie; Ugur Uslu
Journal:  Int J Mol Sci       Date:  2018-08-11       Impact factor: 5.923

Review 10.  Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma.

Authors:  Yasuo Tanaka; Ryosuke Tateishi; Kazuhiko Koike
Journal:  Int J Mol Sci       Date:  2018-10-08       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.